Not logged in...
About USC Norris
Research
Patient Care
CISO
Search Trials
FAQ - Trials
Contact Us - Trials
Membership
Education
Shared Resources
Support USC Norris
Outreach
Login/Logout
Contact USC Norris
Support Us
Donate
Menu
USC Norris
»
Clinical Trials
Trial SWOG-S1211
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High-Risk Multiple Myeloma (HRMM).
Type:
Treatment
Phase:
Phase I/II
Status:
Not Open (Closed)
Treatments:
Anti-Angiogenesis, Chemotherapy: Systemic, Immunomodulator, Immunotherapy
Randomized:
Yes
USC Satellite Location:
None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:
Kevin Kelly, M.D.
Other Trial Staff:
Christine Duran, D.M., Melissa Peralta, D.M., Sondra Ortiz, R.N., Teresa Olea, R.N.
Staff may
log in
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
clinical.trials@med.usc.edu
.
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.